男性乳腺癌肿瘤微环境，重点关注 TIL（肿瘤浸润淋巴细胞）和 PD-L1 表达

Male breast cancer (MBC) is rare and usually presents as a locally advanced disease. Stromal tumor-infiltrating lymphocytes (sTILs) are associated with a better response to neoadjuvant chemotherapy and improved prognosis in all molecular subtypes of female breast cancer, but their role in MBC is less clear.

We studied sTILs and the expression of programmed cell death ligand 1 (PD-L1) and pan-TRK in MBC.

We retrospectively studied 113 cases of MBC surgically treated between 1988 and 2015. The tumors were evaluated for histological type and grade, stage, intrinsic subtype and sTILs.

We performed immunohistochemistry for PD-L1 (clone SP142) and pan-TRK (clone EPR17341) on tissue microarrays. Pan-TRK positive cases were further analyzed by next-generation sequencing. The median age was 69 years (range 60−77). Invasive carcinoma of no special type was found in 94. 7% of cases, of which 53. 1% were grade 2. Estrogen receptor was positive in 92% of the tumors, progesterone receptor in 85. 8%, androgen receptor in 70. 8%; 4.

4% were human epidermal growth factor receptor 2 (HER2)-positive, and 55. 8% HER2-low. 40. 7% of tumors were luminal A and 51. 3% luminal B, 4. 4% HER2-enriched and 3. 5% triple negative carcinoma. sTILs density was <50% in 96. 4% of the tumors, >50% in 3. 6% of the tumors. PD-L1 immune cell score >1% was found in 7. 1% of the tumors (all of luminal subtype). A weak focal cytoplasmic pan-TRK staining was present in 8. 8% but without NTRK fusion. Neither sTILs nor PD-L1 had statistically significant outcomes.

Our findings suggest that a subset of MBC patients harbors an immunological environment characterized by increased sTILs with PD-L1 expression. These patients may potentially benefit from immune checkpoint inhibitor therapy. Frequent HER2-low may offer novel anti-HER2 treatment options.